GID BIO Blog
Read Updates from GID BIO.
GID BIO aims to close a healthcare gap with the launch of a cost-effective treatment for those suffering from osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis due to the increasing number of U.S. adults 65 and older
GID BIO’s results in randomized controlled Phase IIb clinical study support an evidence-based, data-driven approach to treat pain-management caused by osteoarthritis of the knee
While minimally invasive treatments transformed cardiology decades ago, advancements in orthopedic medicine are introducing potential alternatives to traditional surgery by
GID BIO, a cellular therapy company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system
AMA grants two Category III CPT® codes, paving the way for reimbursement strategies GID BIO’s unique autologous cellular implant
GID BIO complete pivotal Phase IIb clinical trial
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the
Interventional Orthopedics and cell-based therapy
Interventional Orthopedics and cell-based therapy Companies and clinics tout the promise of cellular therapy (usually as a “stem cell therapy”)
Interventional Orthopedics and cell-based therapy
Companies and clinics tout the promise of cellular therapy (usually as a “stem cell therapy”) backed by little more than
